Predicting antibody developability profiles through early stage discovery screening

Bailly, M., Mieczkowski, C., Juan, V., et al.

mAbs 2020, vol: 12(1) doi: 10.1080/19420862.2020.1743053

Abstract

Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term ‘developability’ encompasses the feasibility of molecules to successfully progress from discovery to development via evaluation of their physicochemical properties. These properties include the tendency for self-interaction and aggregation, thermal stability, colloidal stability, and optimization of their properties through sequence engineering. Selection of the best antibody molecule based on biological function, efficacy, safety, and developability allows for a streamlined and successful CMC phase. An efficient and practical high-throughput developability workflow (100 s-1,000 s of molecules) implemented during early antibody generation and screening is crucial to select the best lead candidates. This involves careful assessment of critical developability parameters, combined with binding affinity and biological properties evaluation using small amounts of purified material (<1 mg), as well as an efficient data management and database system. Herein, a panel of 152 various human or humanized monoclonal antibodies was analyzed in biophysical property assays. Correlations between assays for different sets of properties were established. We demonstrated in two case studies that physicochemical properties and key assay endpoints correlate with key downstream process parameters. The workflow allows the elimination of antibodies with suboptimal properties and a rank ordering of molecules for further evaluation early in the candidate selection process. This enables any further engineering for problematic sequence attributes without affecting program timelines.

View Publication

Topics: Prometheus, nanoDSF, Antibodies, Publications

Previous Article
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

Up next
nanoDSF: In vitro label-free method to monitor Picornavirus uncoating and test compounds affecting particle stability
nanoDSF: In vitro label-free method to monitor Picornavirus uncoating and test compounds affecting particle stability

×

Sign up to receive
the latest NanoTemper news, product updates, event announcements and more

First Name
Last Name
Company Name
Country
State
Province
State
Region
State
Canton
Agree to Subscribe & Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
Thank you!
Error - something went wrong!